BioCentury
ARTICLE | Financial News

Gilead maintains guidance as HCV sales shrink

November 1, 2016 11:22 PM UTC

In its 3Q16 earnings statement, Gilead Sciences Inc. (NASDAQ:GILD) reported continued flagging sales for HCV treatments Harvoni ledipasvir/sofosbuvir and Sovaldi sofosbuvir. It said the decline in HCV sales was partially offset by increased sales in HIV products.

Gilead reported $7.41 billion in total 3Q16 revenue, down 10% from $8.21 billion in 3Q15 and shy of the $7.45 billion consensus. The company reiterated its previous guidance of $29.5-$30.5 billion in 2016 sales. It had lowered guidance in July in response to slowing sales and deeper discounts for Harvoni (see BioCentury Extra, July 25)...

BCIQ Company Profiles

Gilead Sciences Inc.